Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma.
adrenal cancer
adrenocortical cancer
immunotherapy
ipilimumab
nivolumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
06
2023
accepted:
11
08
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 - 33%. We describe the case of a 32 year old patient who was initially thought to have an inoperable clear cell renal cell carcinoma and was treated with immunotherapy with ipilimumab and nivolumab. The patient had an excellent partial response to treatment. Further work-up prior to consideration of surgery demonstrated that the tumour was an ACC, rather than a renal cancer. She had a right adrenalectomy and right hepatectomy, achieving an R0 resection and remains disease-free one year after surgery. This case illustrates the challenge of diagnosing ACC, and that doublet immunotherapy with ipilimumab and nivolumab can have significant clinical efficacy in ACC.
Sections du résumé
Background
UNASSIGNED
Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 - 33%.
Case presentation
UNASSIGNED
We describe the case of a 32 year old patient who was initially thought to have an inoperable clear cell renal cell carcinoma and was treated with immunotherapy with ipilimumab and nivolumab. The patient had an excellent partial response to treatment. Further work-up prior to consideration of surgery demonstrated that the tumour was an ACC, rather than a renal cancer. She had a right adrenalectomy and right hepatectomy, achieving an R0 resection and remains disease-free one year after surgery.
Conclusion
UNASSIGNED
This case illustrates the challenge of diagnosing ACC, and that doublet immunotherapy with ipilimumab and nivolumab can have significant clinical efficacy in ACC.
Identifiants
pubmed: 37746287
doi: 10.3389/fonc.2023.1242560
pmc: PMC10516602
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1242560Informations de copyright
Copyright © 2023 Charles, Madhu, Powles, Boyde, Hughes, Kumar and Moorcraft.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2021 Apr 12;10(1):1908771
pubmed: 33889439
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686-1695
pubmed: 29452402
J Immunother Cancer. 2018 Oct 22;6(1):111
pubmed: 30348224
Dtsch Arztebl Int. 2010 Dec;107(50):885-91
pubmed: 21246024
J Immunother Cancer. 2019 Sep 18;7(1):253
pubmed: 31533818
J Clin Oncol. 2020 Jan 1;38(1):71-80
pubmed: 31644329
Cancer. 2021 Mar 15;127(6):840-849
pubmed: 33216356
J Clin Pathol. 2015 Jan;68(1):12-7
pubmed: 25315900
J Endocr Soc. 2019 Oct 11;3(12):2295-2304
pubmed: 31745526
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6193-6200
pubmed: 31276163
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107
Lancet Oncol. 2017 Aug;18(8):1022-1039
pubmed: 28687376
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807